Waning Effectiveness of the Third Dose of the BNT162b2 mRNA COVID-19 Vaccine

Tal Patalon, Yaki Saciuk, Asaf Peretz, Galit Perez, Yoav Lurie, Yasmin Maor, Sivan Gazit
doi: https://doi.org/10.1101/2022.02.25.22271494

Article Information

doi 
https://doi.org/10.1101/2022.02.25.22271494
History 
  • February 26, 2022.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Author Information

  1. Tal Patalon, MD1,2,*,
  2. Yaki Saciuk, MPH MA1,
  3. Asaf Peretz, MD2,3,
  4. Galit Perez, MN MA2,
  5. Yoav Lurie4,
  6. Yasmin Maor, MD5,6 and
  7. Sivan Gazit, MD MA1,2
  1. 1Kahn Sagol Maccabi (KSM) Research & Innovation Center, Maccabi Healthcare Services, Tel Aviv, 68125, Israel
  2. 2Maccabitech Institute for Research and Innovation, Maccabi Healthcare Services, Israel
  3. 3Internal Medicine COVID-19 Ward, Samson Assuta Ashdod University Hospital, Ashdod Israel
  4. 4Liver unit, Shaare Zedek City Center Campus, Jerusalem, Israel
  5. 5Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
  6. 6Infectious Disease Unit, Edith Wolfson Medical Centre, Holon, Israel
  1. ↵*Corresponding author. Correspondence to:
    Tal Patalon, patalon_t{at}mac.org.il, 27 HaMared street, Tel Aviv, 68125, Israel
Back to top
Posted February 26, 2022.
Download PDF
Data/Code
Email
Waning Effectiveness of the Third Dose of the BNT162b2 mRNA COVID-19 Vaccine
Tal Patalon, Yaki Saciuk, Asaf Peretz, Galit Perez, Yoav Lurie, Yasmin Maor, Sivan Gazit
medRxiv 2022.02.25.22271494; doi: https://doi.org/10.1101/2022.02.25.22271494
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area